Format

Send to

Choose Destination
Eur Arch Otorhinolaryngol. 2018 Nov;275(11):2851-2859. doi: 10.1007/s00405-018-5126-x. Epub 2018 Sep 18.

Adherence to ATA 2015 guidelines in the management of unifocal non-invasive papillary thyroid cancer: a clinical survey among endocrinologists and surgeons.

Author information

1
Endocrine Institute, Assaf Harofeh Center, Tzrifin, Beer Yaakov, 70300, Israel. or.karen@gmail.com.
2
Endocrine Institute, Assaf Harofeh Center, Tzrifin, Beer Yaakov, 70300, Israel.
3
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
4
Department of ENT, Assaf Harofeh Medical Center, Tzrifin, Beer Yacov, 73000, Israel.

Abstract

BACKGROUND:

Despite updated guidelines, management of thyroid nodules remains controversial. We aim to check implementation of new guidelines by ear-nose-throat (ENT) surgeons and endocrinologists.

METHODS:

A questionnaire was e-mailed including demographic data and an index case: a healthy 26-year-old women with a 3-cm Bethesda III (B3) atypia of undetermined significance solitary nodule and eventually papillary thyroid cancer (PTC).

RESULTS:

Respondent rate was 50.5%, 93 endocrinologists, 55 surgeons. For this case, 77.4% would repeat fine-needle aspiration (FNA), 25.3% order molecular analysis and 22.6% do surgery. If repeated FNA remained B3, 51% would choose surgery, 17.3% molecular analysis and 31.6% follow-up only. If repeated FNA was B6, 58.5% would recommend total (TTx) and 41.5% hemithyroidectomy (HTx). In pathologically confirmed PTC after HTx, 42.4% would recommend completion, 26.8% radioactive iodine (RAI) treatment. For a > = 4-cm tumor, 49.2% would recommend TTx. For a tumor 2-4 cm, 41% would recommend TTx. Variables favoring TTx were family history and radiation exposure. Only 17.4% would prefer TTx when small benign contralateral tumor is present. Reassessment at 1 year with undetectable thyroglobulin (Tg) included stimulated Tg (stTg) (72.5%), neck US only (27.5%) and combined US-stTg (59.4%); only 10.3% would order a diagnostic scan. For recurrence in two (13-9 mm) lymph nodes, 59.3% recommend reoperation, 16.3% RAI and 24.4% active surveillance. There were no major differences between endocrinologists and ENT surgeons.

CONCLUSIONS:

We report a considerable lack of adherence to new guidelines, with only 50% recommending HTx for a 4-cm unifocal low-risk PTC tumor.

KEYWORDS:

Approach; Guidelines; Oncology; Papillary thyroid cancer; Survey; Thyroid

PMID:
30229453
DOI:
10.1007/s00405-018-5126-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center